BIOSYNTHETIC PATHWAYS AND METHODS
First Claim
1. A recombinant microbial cell modified to exhibit increased biosynthesis of a TCA derivative compared to a wild-type control.
1 Assignment
0 Petitions
Accused Products
Abstract
This disclosure describes a recombinant microbial cells and methods of making and using such recombinant microbial cells. Generally, the recombinant cells may be modified to exhibit increased biosynthesis of a TCA derivative compared to a wild-type control. In some embodiments, the TCA derivative can include 1,4-butanediol. In various embodiments, the microbial cell is a fungal cell or a bacterial cell. In some embodiments, the increased biosynthesis of the TCA derivative can include an increase in xylose dehydrogenase activity, xylonolactonase activity, xylonate dehydratase activity, or 2-keto-3-deoxyaldonic acid dehydratase activity.
5 Citations
134 Claims
-
1. A recombinant microbial cell modified to exhibit increased biosynthesis of a TCA derivative compared to a wild-type control.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)
-
2. The recombinant cell of claim 1 wherein the TCA derivative comprises 1,4-butanediol.
-
3. The recombinant microbial cell of claim 1 wherein the microbial cell is a fungal cell.
-
4. The recombinant cell of claim 3 wherein the fungal cell is a member of the Saccharomycetaceae family.
-
5. The recombinant cell of claim 3 wherein the fungal cell is Saccharomyces cerevisiae, Candida rugosa, or Candida albicans.
-
6. The recombinant cell of claim 1 wherein the microbial cell is a bacterial cell.
-
7. The recombinant cell of claim 6 wherein the bacterial cell is a member of the phylum Protobacteria.
-
8. The recombinant cell of claim 7 wherein the bacterial cell is a member of the Enterobacteriaceae family.
-
9. The recombinant cell of claim 8 wherein the bacterial cell is Escherichia coli.
-
10. The recombinant cell of claim 7 wherein the bacterial cell is a member of the Pseudomonaceae family.
-
11. The recombinant cell of claim 10 wherein the bacterial cell is Pseudomonas putida.
-
12. The recombinant cell of claim 6 wherein the bacterial cell is a member of the phylum Firmicutes.
-
13. The recombinant cell of claim 12 wherein the bacterial cell is a member of the Bacillaceae family.
-
14. The recombinant cell of claim 13 wherein the bacterial cell is Bacillus subtilis.
-
15. The recombinant cell of claim 12 wherein the bacterial cell is a member of the Streptococcaceae family.
-
16. The recombinant cell of claim 15 wherein the bacterial cell is Lactococcus lactis.
-
17. The recombinant cell of claim 12 wherein the bacterial cell is a member of the Clostridiaceae family.
-
18. The recombinant cell of claim 17 wherein the bacterial cell is Clostridium cellulolyticum.
-
19. The recombinant cell of claim 6 wherein the bacterial cell is a member of the phylum Cyanobacteria.
-
20. The recombinant cell of claim 1 wherein the microbial cell is photosynthetic.
-
21. The recombinant cell of claim 1 wherein the microbial cell is cellulolytic.
-
22. The recombinant cell of claim 1 wherein the increased biosynthesis of the TCA derivative comprises an increase in xylose dehydrogenase activity, xylonolactonase activity, xylonate dehydratase activity, or 2-keto-3-deoxyaldonic acid dehydratase activity.
-
23. The recombinant cell of claim 22 wherein the increased biosynthesis of the TCA derivative further comprises an increase in benzoylformate decarboxylase activity and an increase in alcohol dehydrogenase activity.
-
24. The recombinant cell of claim 23 wherein the benzoylformate decarboxylase comprises BFD of Pseudomonas putida.
-
25. The recombinant cell of claim 23 wherein the alcohol dehydrogenase comprises yqhD of E. coli.
-
26. The recombinant cell of claim 22 wherein the increased biosynthesis of the TCA derivative further comprises an increase in decarboxylase activity and an increase in alcohol dehydrogenase activity.
-
27. The recombinant cell of claim 26 wherein the decarboxylase comprises KIVD of Lactococcus lactis.
-
28. The recombinant cell of claim 26 wherein the alcohol dehydrogenase comprises yqhD of E. coli.
-
29. The recombinant cell of claim 1 wherein the increased biosynthesis of the TCA derivative comprises a decrease in α
- -ketoglutaric semialdehyde dehydrogenase activity.
-
30. The recombinant cell of claim 1 wherein the increased biosynthesis of the TCA derivative comprises a decrease in aldolase activity.
-
31. The recombinant cell of claim 1 wherein the increased biosynthesis of the TCA derivative comprises a decrease in 2-keto-3-deoxy gluconate aldolase activity.
-
32. The recombinant cell of claim 1 comprising an engineered metabolic pathway for converting 2,5-dioxopentanoic acid to 1,4-butanediol.
-
33. The recombinant cell of claim 32 wherein the engineered metabolic pathway for converting 2,5-dioxopentanoic acid to 1,4-butanediol comprises an enzyme that converts 2,5-dioxopentonoic acid into succinaldehyde.
-
34. The recombinant cell of claim 33 wherein the enzyme that converts 2,5-dioxopentonoic acid into succinaldehyde comprises a 2-ketoacid decareboxylase or a 2-oxoglutarate decarboxylase.
-
35. The recombinant cell of claim 33 wherein the enzyme that converts 2,5-dioxopentonoic acid into succinaldehyde comprises KIVD, BFD, or IPDC.
-
36. The recombinant cell of claim 32 wherein the engineered metabolic pathway for converting 2,5-dioxopentanoic acid to 1,4-butanediol comprises an enzyme that converts succinaldehyde to 1,4-butanediol.
-
37. The recombinant cell of claim 36 wherein the enzyme that converts succinaldehyde to 1,4-butanediol comprises an alcohol dehydrogenase.
-
38. The recombinant cell of claim 36 wherein the enzyme that converts succinaldehyde to 1,4-butanediol comprises YqhD, ADH6, YjgB, or YahK.
-
39. The recombinant cell of claim 32 wherein the engineered metabolic pathway for converting 2,5-dioxopentanoic acid to 1,4-butanediol comprises an enzyme that converts 2,5-dioxopentonoic acid into 2-keto-5-hydroxy-pentanoic acid.
-
40. The recombinant cell of claim 39 wherein the enzyme that converts 2,5-dioxopentonoic acid into 2-keto-5-hydroxy-pentanoic acid comprises an alcohol dehydrogenase.
-
41. The recombinant cell of claim 39 wherein the enzyme that converts 2,5-dioxopentonoic acid into 2-keto-5-hydroxy-pentanoic acid comprises YqhD, ADH6, YjgB, or YahK.
-
42. The recombinant cell of claim 39 wherein the engineered metabolic pathway for converting 2,5-dioxopentanoic acid to 1,4-butanediol comprises an enzyme that converts 2-keto-5-hydroxy-pentanoic acid to 4-hydroxy-1-butyraldehyde.
-
43. The recombinant cell of claim 42 wherein the enzyme that converts 2-keto-5-hydroxy-pentanoic acid to 4-hydroxy-1-butyraldehyde comprises a 2-ketoacid decareboxylase or a 2-oxoglutarate decarboxylase.
-
44. The recombainant cell of claim 42 wherein the enzyme that converts 2-keto-5-hydroxy-pentanoic acid to 4-hydroxy-1-butyraldehyde comprises Kivd, BFD, or IPDC.
-
45. The recombinant cell of claim 42 wherein the engineered metabolic pathway for converting 2,5-dioxopentanoic acid to 1,4-butanediol comprises an enzyme that converts 4-hydroxy-1-butyraldehyde to 1,4-butanediol.
-
46. The recombinant cell of claim 45 wherein the enzyme that converts 4-hydroxy-1-butyraldehyde to 1,4-butanediol comprises an alcohol dehydrogenase.
-
47. The recombinant cell of claim 45 wherein the enzyme that converts 4-hydroxy-1-butyraldehyde to 1,4-butanediol comprises YqhD, ADH6, YjgB, or YahK.
-
48. The recombinant cell of claim 1, further comprising an engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid.
-
49. The recombinant cell of claim 48 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts D-arabinose into D-arabinolactone.
-
50. The recombinant cell of claim 49 wherein the enzyme that can convert D-arabinose into D-arabinolactone comprises a pentose dehydrogenase.
-
51. The recombinant cell of claim 49 wherein the enzyme that can convert D-arabinose into D-arabinonolactone comprises AraDH.
-
52. The recombinant cell of claim 49 wherein the recombinant cell exhibits conversion of D-arabinose into D-arabinonolactone at a level at least 110% of a wild-type control cell.
-
53. The recombinant cell of claim 49 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts D-arabononic acid to 2-oxo-4(s),5-dihydroxy-pentanoic acid.
-
54. The recombinant cell of claim 53 wherein the enzyme that converts D-arabononic acid to 2-oxo-4(s),5-dihydroxy-pentanoic acid comprises an aldonic acid dehydratase.
-
55. The recombinant cell of claim 53 wherein the enzyme that converts D-arabononic acid to 2-oxo-4(s),5-dihydroxy-pentanoic acid comprises AraD.
-
56. The recombinant cell of claim 53 wherein the recombinant cell exhibits conversion of D-arabononic acid to 2-oxo-4(s),5-dihydroxy-pentanoic acid at a level at least 110% of a wild-type control cell.
-
57. The recombinant cell of claim 49 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 2-oxo-4(s),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid.
-
58. The recombinant cell of claim 57 wherein the enzyme that converts 2-oxo-4(s),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid comprises a 2-keto-3-deoxyaldonic acid dehydratase.
-
59. The recombinant cell of claim 57 wherein the enzyme that converts 2-oxo-4(s),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid comprises KdaD.
-
60. The recombinant cell of claim 57 wherein the recombinant cell exhibits conversion of 2-oxo-4(s),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid at a level at least 110% of a wild-type control cell.
-
61. The recombinant cell of claim 48 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts D-xylose to D-xylonolactone.
-
62. The recombinant cell of claim 61 wherein the enzyme that converts D-xylose to D-xylonolactone comprises a pentose dehydrogenase.
-
63. The recombinant cell of claim 61 wherein enzyme that converts D-xylose to D-xylonolactone comprises XylB or rrnAC3034.
-
64. The recombinant cell of claim 61 wherein the recombinant cell exhibits conversion of D-xylose to D-xylonolactone at a level at least 110% of a wild-type control.
-
65. The recombinant cell of claim 61 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts D-xylonolactone to D-xylonic acid.
-
66. The recombinant cell of claim 65 wherein the enzyme that converts D-xylonolactone to D-xylonic acid comprises a pentonolactonase.
-
67. The recombinant cell of claim 65 wherein the enzyme that converts D-xylonolactone to D-xylonic acid comprises XylC or rrnAC3033.
-
68. The recombinant cell of claim 65 wherein the recombinant cell exhibits conversion of D-xylonolactone to D-xylonic acid at a level at least 110% of a wild-type control.
-
69. The recombinant cell of claim 61 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts D-xylonic acid to 2-oxo-4(S),5-dihydroxy-pentanoic acid.
-
70. The recombinant cell of claim 69 wherein the enzyme that converts D-xylonic acid to 2-oxo-4(S),5-dihydroxy-pentanoic acid comprises an aldonic acid dehydratase.
-
71. The recombinant cell of claim 69 wherein the enzyme that converts D-xylonic acid to 2-oxo-4(S),5-dihydroxy-pentanoic acid comprises XylD or rrnAC3032.
-
72. The recombinant cell of claim 69 wherein the recombinant cell exhibits conversion of D-xylonic acid to 2-oxo-4(S),5-dihydroxy-pentanoic acid at a level at least 110% of a wild-type control.
-
73. The recombinant cell of claim 61 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 2-oxo-4(S),5-dihydroxy-pentanoic acid to 2,5-dioxopenatnoic acid.
-
74. The recombinant cell of claim 73 wherein the enzyme that converts 2-oxo-4(S),5-dihydroxy-pentanoic acid to 2,5-dioxopenatnoic acid comprises a 2-keto-3-deoxyaldonic acid dehydratase.
-
75. The recombinant cell of claim 73 wherein the enzyme that converts 2-oxo-4(S),5-dihydroxy-pentanoic acid to 2,5-dioxopenatnoic acid comprises XylX or rrnAC3039.
-
76. The recombinant cell of claim 73 wherein the recombinant cell exhibits conversion of 2-oxo-4(S),5-dihydroxy-pentanoic acid to 2,5-dioxopenatnoic acid at a level at least 110% of a wild-type control.
-
77. The recombinant cell of claim 48 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts L-arabinose to L-arabinolactone.
-
78. The recombinant cell of claim 77 wherein the enzyme that converts L-arabinose to L-arabinolactone comprises a pentose dehydrogenase.
-
79. The recombinant cell of claim 77 wherein the enzyme that converts L-arabinose to L-arabinolactone comprises AraE.
-
80. The recombinant cell of claim 77 wherein the recombinant cell exhibits conversion of L-arabinose to L-arabinolactone at a level at least 110% of a wild-type control.
-
81. The recombinant cell of claim 77 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts L-arabinolactone to L-arabinonic acid.
-
82. The recombinant cell of claim 81 wherein the enzyme that converts L-arabinolactone to L-arabinonic acid comprises a pentonolactonase.
-
83. The recombinant cell of claim 81 wherein the enzyme that converts L-arabinolactone to L-arabinonic acid comprises Arai.
-
84. The recombinant cell of claim 81 wherein the recombinant cell exhibits conversion of L-arabinolactone to L-arabinonic acid at a level at least 110% of a wild-type control.
-
85. The recombinant cell of claim 77 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts L-arabinonic acid to 2-oxo-4(R),5-dihydroxy-pentanoic acid.
-
86. The recombinant cell of claim 85 wherein the enzyme that converts L-arabinonic acid to 2-oxo-4(R),5-dihydroxy-pentanoic acid comprises an aldonic acid dehydratase.
-
87. The recombinant cell of claim 85 wherein the enzyme that converts L-arabinonic acid to 2-oxo-4(R),5-dihydroxy-pentanoic acid comprises AraB.
-
88. The recombinant cell of claim 81 wherein the recombinant cell exhibits conversion of L-arabinonic acid to 2-oxo-4(R),5-dihydroxy-pentanoic acid at a level at least 110% of a wild-type control.
-
89. The recombinant cell of claim 77 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 2-oxo-4(R),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid.
-
90. The recombinant cell of claim 89 wherein the enzyme that converts 2-oxo-4(R),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid comprises a 2-keto-3-deoxyaldonic acid dehydratase.
-
91. The recombinant cell of claim 89 wherein the enzyme that converts 2-oxo-4(R),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid comprises AraD.
-
92. The recombinant cell of claim 89 wherein the recombinant cell exhibits conversion of 2-oxo-4(R),5-dihydroxy-pentanoic acid to 2,5-dioxopentanoic acid at a level at least 110% of a wild-type control.
-
93. The recombinant cell of claim 48 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts D-glucaric acid to 4-deoxy-5-keto-D-glucaric acid.
-
94. The recombinant cell of claim 93 wherein the enzyme that converts D-glucaric acid to 4-deoxy-5-keto-D-glucaric acid comprises an aldonic acid dehydratase.
-
95. The recombinant cell of claim 93 wherein the enzyme that converts D-glucaric acid to 4-deoxy-5-keto-D-glucaric acid comprises YcbF.
-
96. The recombinant cell of claim 93 wherein the recombinant cell exhibits conversion of D-glucaric acid to 4-deoxy-5-keto-D-glucaric acid at a level at least 110% of a wild-type control.
-
97. The recombinant cell of claim 93 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 4-deoxy-5-keto-D-glucaric acid to 2,5-dioxopentanoic acid.
-
98. The recombinant cell of claim 97 wherein the enzyme that converts 4-deoxy-5-keto-D-glucaric acid to 2,5-dioxopentanoic acid comprises a 2-keto-3-deoxyaldonic acid dehydratase.
-
99. The recombinant cell of claim 97 wherein the enzyme that converts 4-deoxy-5-keto-D-glucaric acid to 2,5-dioxopentanoic acid comprises YcbC.
-
100. The recombinant cell of claim 48 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts D-galactaric acid to 4-deoxy-5-keto-D-glucaric acid.
-
101. The recombinant cell of claim 100 wherein the enzyme that converts D-galactaric acid to 4-deoxy-5-keto-D-glucaric acid comprises an aldonic acid dehydratase.
-
102. The recombinant cell of claim 100 wherein the enzyme that converts D-galactaric acid to 4-deoxy-5-keto-D-glucaric acid comprises YcbH.
-
103. The recombinant cell of claim 100 wherein the recombinant cell exhibits conversion of D-galactaric acid to 4-deoxy-5-keto-D-glucaric acid at a level at least 110% of a wild-type control.
-
104. The recombinant cell of claim 100 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 4-deoxy-5-keto-D-glucaric acid to 2,5-dioxopentanoic acid.
-
105. The recombinant cell of claim 104 wherein the enzyme that converts 4-deoxy-5-keto-D-glucaric acid to 2,5-dioxopentanoic acid comprises a 2-keto-3-deoxyaldonic acid dehydratase.
-
106. The recombinant cell of claim 104 wherein the enzyme that converts 4-deoxy-5-keto-D-glucaric acid to 2,5-dioxopentanoic acid comprises YcbC.
-
107. The recombinant cell of claim 48 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 4(R)-hydroxy-L-proline to 4(R)-hydroxy-D-proline.
-
108. The recombinant cell of claim 107 wherein the enzyme that converts 4(R)-hydroxy-L-proline to 4(R)-hydroxy-D-proline comprises an amino acid transporter.
-
109. The recombinant cell of claim 107 wherein the enzyme that converts 4(R)-hydroxy-L-proline to 4(R)-hydroxy-D-proline comprises LysE or HypE.
-
110. The recombinant cell of claim 107 wherein the recombinant cell exhibits conversion of 4(R)-hydroxy-L-proline to 4(R)-hydroxy-D-proline at a level at least 110% of a wild-type control.
-
111. The recombinant cell of claim 107 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 4(R)-hydroxy-D-proline to 2-carboxy-4(R)-hydroxy-δ
- -pyrroline.
-
112. The recombinant cell of claim 111 wherein the enzyme that converts 4(R)-hydroxy-D-proline to 2-carboxy-4(R)-hydroxy-δ
- -pyrroline comprises HypOX.
-
113. The recombinant cell of claim 111 wherein the recombinant cell exhibits conversion of 4(R)-hydroxy-D-proline to 2-carboxy-4(R)-hydroxy-δ
- -pyrroline at a level at least 110% of a wild-type control.
-
114. The recombinant cell of claim 107 wherein the engineered metabolic pathway for converting a carbon source to 2,5-dioxopentanoic acid comprises an enzyme that converts 2-oxo-4(R),5-hydroxy-5-aminopentanoic acid to 2,5-dioxopentanoic acid.
-
115. The recombinant cell of claim 114 wherein the enzyme that converts 2-oxo-4(R),5-hydroxy-5-aminopentanoic acid to 2,5-dioxopentanoic acid comprises a 2-keto-3-deoxyaldonic acid dehydratase.
-
116. The recombinant cell of claim 114 wherein the enzyme that converts 2-oxo-4(R),5-hydroxy-5-aminopentanoic acid to 2,5-dioxopentanoic acid comprises PP1247.
-
117. The recombinant cell of claim 114 wherein the recombinant cell exhibits conversion of 2-oxo-4(R),5-hydroxy-5-aminopentanoic acid to 2,5-dioxopentanoic acid at a level at least 110% of a wild-type control.
-
118. The recombinant cell of claim 48 modified to exhibit increased α
- -ketoglutaric semialdehyde dehydrogenase activity compared to a wild-type control.
-
119. The recombinant cell of claim 118 exhibiting increased conversion of 2,5-dioxopentanoic acid to a TCA derivative compared to a wild-typ control.
-
120. The recombinant cell of claim 119 wherein the TCA derivative comprises succinate, fumarate, malate, glutamate, lysine, threonine, or 4-hydroxybutyrate.
-
121. The recombinant cell of claim 1 genetically modified to increase consumption of xylose, arabinose, glucaric acid, galactaric acid, or hydroxyproline compared to a wild-type control.
-
122. The recombinant cell of claim 1 genetically modified to increase consumption of a uronic acid compared to a wild-type control.
-
123. The recombinant cell of claim 122 wherein the uronic acid comprises galacturonic acid or glucuronic acid.
-
124. The recombinant cell of claim 122 genetically modified to increase conversion of the uronic acid to an aldonic acid compared to a wild-type control.
-
125. The recombinant cell of claim 122 wherein the recombinant cell comprises an exogenous urinate dehydrogenase.
-
126. A method comprising:
incubating the recombinant cell of claim 1 in medium that comprises a carbon source under conditions effective for the recombinant cell to produce a TCA derivative.
-
127. The method of claim 126 wherein the TCA derivative comprises 1,4-butanediol.
-
128. The method of claim 126 wherein the carbon source comprises xylose, arabinose, glucaric acid, galactaric acid, or hydroxyproline.
-
129. The method of claim 126 wherein the increased biosynthesis of the TCA derivative comprises an increase in pentose dehydrogenase activity, pentonolactonase activity, aldonic acid dehydratase activity, or 2-keto-3-deoxyaldonic acid dehydratase activity.
-
130. The method of claim 126 wherein the increased biosynthesis of the TCA derivative comprises an increase in hexic acid dehydratase activity or 5-dehydro-4-deoxyglucarate dehydratase activity.
-
2. The recombinant cell of claim 1 wherein the TCA derivative comprises 1,4-butanediol.
-
131. A method comprising:
introducing into a host cell a heterologous polynucleotide encoding at least one polypeptide that catalyzes conversion of a carbon source to a TCA derivative, wherein the at least one polypeptide is operably linked to a promoter so that the modified host cell catalyzes conversion of the carbon source to TCA derivative. - View Dependent Claims (132, 133, 134)
-
132. The method of claim 131 wherein the TCA derivative comprises 1,4-butanediol.
-
133. The method of claim 131 wherein the carbon source comprises xylose.
-
134. The method of claim 131 wherein the TCA derivative comprises succinate, fumarate, malate, glutamate, lysine, threonine, 4-hydroxybutyrate.
-
132. The method of claim 131 wherein the TCA derivative comprises 1,4-butanediol.
Specification
- Resources
-
Current AssigneeRegents of The University of Minnesota (University of Minnesota)
-
Original AssigneeRegents of The University of Minnesota (University of Minnesota)
-
InventorsZHANG, Kechun, XIONG, Mingyong
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current1/1
-
CPC Class CodesC12N 15/52 Genes encoding for enzymes ...C12N 9/0006 acting on CH-OH groups as d...C12N 9/0008 acting on the aldehyde or o...C12N 9/18 Carboxylic ester hydrolases...C12N 9/88 Lyases (4.)C12P 7/18 polyhydricC12Y 101/01 with NAD+ or NADP+ as accep...C12Y 101/01001 Alcohol dehydrogenase (1.1....C12Y 102/01026 2,5-Dioxovalerate dehydroge...C12Y 301/01 Carboxylic ester hydrolases...C12Y 301/01068 Xylono-1,4-lactonase (3.1.1...C12Y 401/01007 Benzoylformate decarboxylas...C12Y 402/00 Carbon-oxygen lyases (4.2)C12Y 402/01082 Xylonate dehydratase (4.2.1...